Cancer Home > SUTENT

If you have cancer of the pancreas, kidney, or gastrointestinal tract, your healthcare provider may prescribe SUTENT, a chemotherapy medication. This product comes in the form of a capsule and is available in three strengths. It is taken once a day, with or without food. Common side effects include diarrhea, fever, and lack of energy.

What Is SUTENT?

SUTENT® (sunitinib) is a prescription chemotherapy medication approved to treat certain cancers of the kidney, pancreas, and gastrointestinal (GI) tract. It belongs to a group of medicines called tyrosine kinase inhibitors. SUTENT slows the growth of cancer cells; however, it is not a cancer cure.
 
(Click SUTENT Uses for more information on this topic, including possible off-label uses.)
 

Who Makes This Medication?

SUTENT is made by Pfizer Italia S.r.l. and distributed by Pfizer Labs.
 

How Does It Work?

SUTENT works by blocking an enzyme in the body known as tyrosine kinase. This enzyme tells cancer cells to divide and grow. By blocking tyrosine kinase, SUTENT may slow or stop the growth of cancer cells, which can slow down how quickly the disease progresses.
 

Clinical Effects of SUTENT

SUTENT has been shown to extend survival in people with certain types of cancer in clinical trials. One measure of how well a cancer medication works is called "progression-free survival" (PFS). PFS is the period of time during treatment when the cancer does not get worse, or progress.
 
In clinical studies involving people with gastrointestinal stromal tumor (GIST), a rare type of gastrointestinal cancer, people given SUTENT had an additional 18 months of PFS compared to people taking a placebo medication (a "sugar pill" with no active ingredients). Specifically, those taking SUTENT had 24.1 months without cancer progression, compared with 6 months for those taking the placebo. Everyone in the study had previously taken imatinib (Gleevec®) without an adequate response or could not take imatinib.
 
In clinical studies involving people with renal cell carcinoma (kidney cancer), people given SUTENT had an additional 25 months of PFS compared to people taking a different chemotherapy medicine (interferon-alpha). Specifically, people taking SUTENT survived 47.3 months without disease progression, compared to 22 months for those taking the other chemotherapy medication.
 
In clinical studies involving people with pancreatic neuroendocrine tumors (PNET), a form of pancreatic cancer, people given SUTENT had 10.2 months of PFS compared to 5.4 months for people given a placebo.
 
Written by/reviewed by:
Last reviewed by: Kristi Monson, PharmD;
Last updated/reviewed:
List of references (click here):
Other Articles in This eMedTV Presentation
Advertisement


Topics

Medications

Quicklinks

Related Channels

eMedTV Links
Copyright © 2006-2017 Clinaero, Inc.

eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.

This site complies with the HONcode standard for trustworthy health information:
verify here.